Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
anticoagulant
Biotech
Novartis inks $925M Anthos takeover to rejoin clot-busting race
Six years after spinning the asset out, Novartis has struck a deal to buy Anthos to add the clot-busting prospect to its late-phase pipeline.
Nick Paul Taylor
Feb 11, 2025 5:21am
Regeneron anticoagulant bests enoxaparin, matches Eliquis
Dec 19, 2024 8:50am
Blackstone's $250M bet beats Xarelto in phase 2 bleeding trial
Sep 18, 2023 6:00am
BMS, J&J's secondary stroke med doesn't stick the landing
Aug 28, 2022 3:36am
Racing Bayer, Merck gets FDA fast-track tag for anticoagulant
Aug 23, 2022 8:40am
Bayer-Ionis' anti-thrombotic med doesn't increase bleeding
Jul 28, 2022 10:51am